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Abstract
Tumor antigen heterogeneity limits success of chimeric antigen receptor (CAR) T-cell therapies. 
Embryonal carcinomas (ECs) and mixed testicular germ cell tumors (TGCTs) containing EC, 
which are the most aggressive TGCT subtypes, are useful for dissecting this issue as ECs express 
the CD30 antigen but also contain CD30–/dim cells. We found that CD30-redirected CAR T cells 
(CD30.CAR T cells) exhibit antitumor activity in vitro against the human EC cell lines Tera-1, 
Tera-2 and NCCIT, and putative EC stem cells identified by Hoechst dye staining. Cytolytic 
activity of CD30.CAR T cells was complemented by their sustained proliferation and pro-
inflammatory cytokine production. CD30.CAR T cells also demonstrated antitumor activity in an 
in vivo xenograft NSG mouse model of metastatic EC. We observed that CD30.CAR T cells, 
while targeting CD30+ EC tumor cells through the CAR (i.e. antigen-dependent targeting), also 
eliminated surrounding CD30– EC cells in an antigen-independent manner, via cell-cell contact-
dependent Fas/FasL interaction. In addition, ectopic Fas (CD95) expression in CD30+ Fas– EC 
was sufficient to improve CD30.CAR T-cell antitumor activity. Overall, these data suggest that 
CD30.CAR T cells might be useful as an immunotherapy for ECs. Additionally, Fas/FasL 
interaction between tumor cells and CAR T cells can be exploited to reduce tumor escape due to 
heterogeneous antigen expression or to improve CAR T-cell antitumor activity.
Introduction
Immunotherapy is useful in the battle against cancer. Immunotherapies range from 
monoclonal antibody (mAb)-based therapies, for example in the form of immunotoxin 
conjugates or checkpoint inhibitors, to the adoptive transfer of ex vivo expanded tumor-
specific T cells, whose antigen specificity is mediated by their native TCR, by transgenic 
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TCR, or by chimeric antigen receptors (CARs). CARs are chimeric proteins in which an Ab 
single-chain variable fragment (scFv), as an extracellular receptor, is fused with T-cell 
effector and co-stimulatory intracellular domains (1). CAR-based technology overcomes 
some of the limitations of mAb-based immunotherapy because CARs combine the antigen 
specificity of a mAb with intrinsic properties of T lymphocytes (2). In contrast to mAbs, 
CAR-expressing T lymphocytes (CAR T cells) can persist long-term, migrate to the tumor 
site following gradients of chemokines such as CXCL12 (3), and exploit multiple lytic 
functions (4).
One cause of tumor escape and relapse after targeted immunotherapy, including 
immunotherapy by CAR T cells, is the heterogeneous expression of target antigens within 
the tumor. For example, some patients with leukemia showed emergence of CD19– leukemic 
cells after adoptive transfer of CD19-specific CAR T cells due to selection pressure of 
alternatively spliced CD19 isoforms (5). Similarly, tumor escape due to antigen loss has 
been observed in patients with glioblastoma treated with EGFRvIII-specific CAR T cells 
(6). Bispecific CAR T cells that target two antigens simultaneously (7) can reduce tumor 
escape, but may also increase the risk of toxicities in normal tissues due to on-target off-
tumor effects, especially in solid tumors, which frequently share antigens with normal 
tissues. There is a need to overcome tumor escape associated with antigen heterogeneity, 
especially as these otherwise successful immunotherapies move from liquid cancers into the 
arena of solid tumors.
Testicular germ cell tumors (TGCTs), sub-categorized as seminomas and non-seminomas 
(NS-TGCTs), are the most common malignancies in male adolescents and young adults (8). 
Pure embryonal carcinomas (EC), a subtype of NS-TGCTs derived from malignant 
embryonic stem cells, accounts for 2% of all TGCTs (9). More commonly, EC is a 
histologic component in 85% of mixed TGCTs in which multiple subtypes are present (9). 
The presence of EC is associated with poor outcomes (3). CD30, a TNF superfamily 
member with a pro-survival role in transformed stem cells (10), characterizes ECs at 
diagnosis and at relapse (11). Furthermore, the persistence of CD30+ tumor cells post-
chemotherapy is considered a negative prognostic factor (11). Therefore, CD30-targeting 
immunotherapy may improve overall survival while reducing chemotherapy-associated 
morbidities. We have therefore used CD30-redirected CAR T cells (CD30.CAR T cells), a 
validated approach in patients with Hodgkin’s lymphomas and CD30+ non-Hodgkin’s 




The Hodgkin’s lymphoma-derived cell line HDLM-2 was obtained from the German 
Collection of Cell Cultures (DMSZ, Braunschweig, Germany). The Burkitt’s lymphoma-
derived cell line Raji, the EC-derived cell lines NCCIT, Tera-1, and Tera-2, the 
neuroblastoma-derived cell lines Lan-1 and SH-SY5Y, and the leukemia-derived cell line 
K562 were obtained from American Type Culture Collection (ATCC). K562 cells and Lan-1 
cells were transduced with a retroviral vector encoding either human CD19 or CD30 to 
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constitutively express CD19 or CD30, respectively. For CD95 overexpression in NCCIT 
cells, the full-length human CD95 was cloned into the retroviral vector pLXSN. CD95 
siRNA pSUPER vectors were used for CD95 knockdown in Tera-1 cells as described (14). 
Tumor cells or CD30.CAR T cells were labeled with the retroviral vector encoding eGFP-
Firefly-Luciferase (eGFP-FFLuc) for in vivo studies (15). Raji, K562, Lan-1, SH-SY5Y and 
NCCIT cells were maintained in culture with RPMI 1640 medium (Gibco) supplemented 
with 10% fetal bovine serum (Corning), 1X penicillin-streptavidin (Invitrogen), and 2 mM 
GlutaMax (Invitrogen). Tera-1 and Tera-2 cells were maintained with McCoy’s 5A media 
(Corning) with 15% FBS, 1X penicillin-streptavidin, and 2 mM GlutaMax. Cells were 
maintained in culture in a humidified atmosphere containing 5% CO2 at 37°C. Cells were 
kept in culture for less than 6 consecutive months, after which aliquots from the original 
expanded vial were used. Tumor cell lines were routinely tested to exclude contamination 
with mycoplasma and assessed for the expression of CD30 or GD2 by flow cytometry to 
confirm identity.
Retroviral constructs and transduction of T lymphocytes.
We constructed two second-generation CD30.CARs on an SFG retroviral vector backbone 
encoding either the CD28 (CD30.28) or 4–1BB (CD30.BB) endodomains coupled with the 
CD3ζ endodomain (Supplementary Fig. S1A) using the previously reported CD30-specific 
scFv (16). Non-transduced T cells from matched independent experiments or T cells 
transduced with a CD19.CAR encoding the CD28 endodomain (17) were used as controls 
(control T cells) for in vitro and in vivo experiments, respectively. Transient retroviral 
supernatants were produced using 293T cells as previously described (16). Peripheral blood 
mononuclear cells isolated from independent experiments with buffy coats of healthy 
volunteer blood (Gulf Coast Regional Blood Center, Houston, TX) were transduced to 
express the CD30.CARs, GD2.CAR, or CD19.CAR and maintained in culture as previously 
described (18).
Flow cytometry.
The following mAbs conjugated with phycoerythrin (PE), peridinin-chlorophyll-protein 
complex (PerCP), fluorescein isothiocyanate (FITC), allophycocyanin (APC), APC-H7, 
Alexa Fluor 647 (AF 647), Alexa Fluor 700, Brilliant Violet (BV) 421, BV 711, and/or 
peridinin chlorophyll protein (Per-CP) were used: CD3, CD4, CD8, CD30 (Clone Ber-H3), 
CD33, CD45, CD45RA, CD45RO, CD95, CD276 (B7H3), CCR7, GD2 (Clone 14.G2a) and 
active caspase 3 (BD Biosciences). Rabbit antibody to cleaved caspase 7 and Alexa Fluor 
488-conjugated goat anti-rabbit IgG mAbs were purchased from Cell Signaling 
Technologies. Annexin V/7AAD staining was performed according to manufacturer’s 
instructions (BD Biosciences). CAR expression by T cells was detected using an Alexa 
Fluor 647 conjugated goat anti-mouse F(ab’)2 antibody (Jackson Immuno). For T-cell 
immunophenotypes, samples were labeled in a two-step process by anti-F(ab’)2 antibody 
followed by washing in PBS and adding T-cell marker antibodies. To detect CD19.CAR we 
used a specific anti-idiotype antibody (Clone 233–4A) generated by immunizing mice with 
the anti-CD19 scFv followed by APC-conjugated rat anti-mouse IgG secondary mAb (BD 
Biosciences). To detect GD2.CAR we used a specific anti-idiotype antibody 1A7 (19). For 
absolute number calculations, samples were analyzed using CountBright absolute counting 
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beads (Thermo Fisher). For intracellular staining, cells were stained with surface antibodies, 
washed and fixed with Cytofix/Cytoperm (BD), followed by intracellular staining in 1X 
permeabilization buffer per manufacturer’s instructions. Samples were acquired with at least 
10,000 positive events using a FACSCanto II flow cytometer (BD) and analyzed by FlowJo 
(Treestar). FACS sorting was also performed using CD30-PE or CD95-PE labeled tumor 
cells on an Aria III flow cytometer (BD; UNC Flow Cytometry Core Facility).
Side Population (SP) staining by Hoechst dye/Dye Cycle Violet and cell sorting.
For SP analysis, cells were incubated in HBSS (Life Technologies) containing 2% FBS, 10 
mM HEPES (Life Technologies), and either 10 μg/mL Hoechst 33342 (Sigma-Aldrich) or 
10 μM Vybrant DyeCycle Violet (DCV) (Life Technologies) for 90 min at 37°C. Cells were 
then washed with ice cold HBSS and FACS sorted or labeled with CD30-PE for flow 
cytometry analysis. To detect the SP fluorescent phenotype, Hoechst 33342 samples were 
excited using a 355nm UV laser on a LSRII/Fortessa flow cytometer (BD) while DCV 
samples were excited using a 405 nm violet laser on an Aria III flow cytometer. 
Corresponding band-pass filter sets were: blue 450–50 bp/450 LP, 610–20 bp/690 LP 
(LSRII/Fortessa) and 450–50 bp/502 LP (Aria III).
Cytotoxicity assay.
The cytotoxic activity of transduced effector cells was evaluated using a 6-hour 51Cr release 
assay as previously described (16). Labeled target cells were: Raji (CD30–), HDLM-2 
(CD30+), Tera-2, and NCCIT.
In vitro coculture.
Adherent tumor cell lines were plated at 0.1 – 0.25 × 106 cells/mL in a 24-well tissue culture 
plate one day prior to the addition of CD30.CAR T cells or CD19.CAR T cells at various 
effector/target (E:T) ratios. After five days, cells were collected using Versene (UNC Tissue 
Culture Facility) for non-enzymatic dissociation of tumor cells, washed in PBS, labeled with 
fluorescent CD3-APCH7 and CD30-FITC mAbs and analyzed by flow cytometry. In 
experiments with Lan-1/WT or Lan-1/CD30 control tumor cells, remaining cells were 
labeled with CD3-APCH7 and GD2-PE mAbs. For GD2.CAR and SH-SY5Y coculture 
experiments, remaining cells were labeled with CD3-PerCP, CD276-BV421, and GD2-PE 
mAbs. In experiments where CD19.CAR T cells and K562 cells were used, remaining cells 
were also labeled with CD33-APC mAb. Transwell assays were performed using 0.4 μm 
transwells (EMD Millipore) in 24-well tissue culture plates. Tera-1 cells were also cultured 
with coculture supernatant collected at 24hrs or human recombinant IFNγ or TNFα 
(Peprotech) and analyzed for CD30 expression by flow cytometry after 48hrs in culture. For 
detecting T-cell apoptosis in vitro, control T cells or CD30.CAR T cells were cocultured 
with Tera-1/WT or Tera-1/CD95 KD cells at a 1:1 ratio or with anti-Fas agonistic Ab (clone 
CH11, Sigma Aldrich) in low-serum media (2% FBS) (14) for 72hrs followed by Annexin 
V/7AAD staining.
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Carboxyfluorescein succinimidyl ester (CFSE)-based proliferation assay.
CD30.CAR T cells and control T cells were labeled with CFSE (Invitrogen) and cocultured 
with tumor cells at 5:1 E:T ratio. On day 5, cells were collected, labeled with CD3-APCH7, 
CD4-PECy7, and CD8-APC mAbs (BD Biosciences), and analyzed for CFSE dilution by 
flow cytometry. In separate coculture experiments, tumor cells were labeled with CFSE and 
plated one day prior to the addition of control T cells and CD30.CAR T cells. Five days later 
cells were collected and CFSE+ tumor cells were identified by flow cytometry.
Enzyme-linked immunosorbent assay (ELISA).
The release of IL-2 and IFNγ by CD30.CAR T cells was quantified using specific ELISAs 
(R&D Systems) in supernatants collected after 24 hours from T cells cocultured with tumor 
cells.
Reverse transcription quantitative polymerase chain reaction.
Cells were lysed and RNA was extracted using the RNeasy Mini kit (Qiagen) and reverse 
transcribed into cDNA (Superscript VILO, Invitrogen). Human ABCG2 (Hs01053790_m1), 
SOX2 (Hs01053049_s1), and CD95L (Hs00181226_g1) mRNA expression was quantified 
using Taqman probes (Catalog # 4331182, ThermoFisher Scientific) on a Quantstudio 6 
PCR machine (Applied Biosystems) using β-actin as housekeeping gene control 
(Invitrogen).
Xenograft mouse models.
All mouse experiments were performed in accordance with UNC Animal Husbandry and 
Institutional Animal Care and Use Committee (IACUC) guidelines and were approved by 
UNC IACUC. To measure in vivo the growth of EC cells, we used two orthotopic models in 
NOD/SCID/γcnull (NSG) male mice ages 6 to 12 weeks. In the first model, Tera-2 eGFP-
FFLuc cells were resuspended in DPBS (Corning) and injected directly into the left testis (2 
× 106 cells/mice) (20). In the second model, Tera-2 eGFP-FFLuc cells were resuspended in 
Matrigel (Corning) and engrafted under the left kidney capsule (0.25 × 106 cells/mice) (21). 
To assess antitumor activity of CD30.CAR T cells, mice received T cells (1 × 107 cells/
mouse) intravenously via tail vein injection 14 days later, when the bioluminescence 
emission (BLI) of the tumor was consistently measurable. To monitor T-cell localization and 
expansion, mice were engrafted with wild-type (WT) Tera-2 cells and infused 21 days later 
with 1 × 107 control or CD30.CAR T cells transduced with eGFP-FFLuc. The IVIS imaging 
system (Xenogen; UNC Biomedical Imaging Research Center) was used to monitor tumor 
growth or T-cell expansion and localization. Briefly, a constant region of interest was drawn 
over the tumor regions and the intensity of the signal measured as total flux (photon/sec) as 
previously described (21).
Mouse tissue processing and immunohistochemistry (IHC).
T cell-treated mice with tumor engrafted in kidney or testis were sacrificed and tumors were 
fixed in 10% neutral buffered formalin (Fisher Scientific), processed in 3 μm longitudinal 
planes, and stained for hematoxylin/eosin (H&E) and a human CD3 antibody (UNC 
Lineberger Animal Histopathology Core Facility). Blood samples normalized to 100μL total 
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volume and spleen samples were also harvested, lysed to remove red blood cells (ACK Lysis 
Buffer, Gibco), and stained with anti-human CD45 and CD3 for detection of T cells. For 
detection of CD30, mouse tissues and human testes tissue arrays (US Biomax) were stained 
with a human CD30 antibody(Clone Ber-H2, Dako; UNC Translational Pathology 
Laboratory). H score is the cumulative score of the frequency of positive cells x score 
calculated by a membrane staining algorithm, which scores cells based on membrane 
staining intensity (UNC Translational Pathology Laboratory). Tumors collected from tumor 
bearing mice were counted by a board-certified veterinary pathologist (S. Montgomery) 
blinded to experimental conditions. A random tumor field containing at least 80% tumor and 
positively labeled CD3 cells was selected and, depending on tumor size, up to ten high 
power (400X) fields of view were examined using a grid matrix approach (21). Two samples 
from mice treated with either CD30.28 T cells or CD30.BB T cells had sheets of positive 
cells that were too numerous to count (TNTC) and were not included in the quantitative 
analysis.
RNA-Seq.
Briefly, total RNA was extracted from EC cell lines and mRNA libraries were prepared 
(TruSeq Stranded mRNA Library Prep, Illumina) and sequenced on the Illumina HiSeq4000 
platform (UNC High-Throughput Sequencing Facility) using paired-end 100-bp reads, with 
84 million reads on average (range 49–139 million). RNA-seq data was aligned with STAR 
alignment (v2.4.2) and quantified with Salmon (v0.6.0). Differential gene expression 
analysis was performed using the R DESEq2 package (https://
genomebiology.biomedcentral.com/articles/10.1186/s13059-014-0550-8). Among all 
significantly expressed genes between NCCIT, TERA1, and TERA2 cell lines (FDR p-value 
< =0.05), expression was further filtered to genes contained within the KEGG Apoptosis and 
the Biocarta p53 pathway signatures (https://www.ncbi.nlm.nih.gov/pubmed/10592173; 
https://doi.org/10.1089/152791601750294344).
Statistical analysis.
All in vitro data are presented as mean ± SEM. A two-sided, paired Student’s T test was 
used to determine the statistical significance of differences between groups, and p-values 
less than .05 were accepted as indicating a significant difference. When multiple comparison 
analyses were required, statistical significance was evaluated by one-way ANOVA or 
repeated-measures ANOVA for matched T-cell independent experiments followed by two-
sided paired Student’s t test as needed for comparing two groups. Statistical significance for 
differences in tumor growth in vivo were evaluated by one-way ANOVA. Differences in 
survival curves for mouse experiments were compared by log-rank (Mantel-Cox) test.
Results
EC cell lines and TGCT tissue specimens express CD30.
We assessed the expression of CD30 in three human EC cell lines (Tera-1, Tera-2, and 
NCCIT) by flow cytometry, and used wild type Lan-1 (Lan-1/WT) and CD30+ Lan-1 
(Lan-1/CD30) cells as negative and positive controls, respectively. The HDLM-2 Hodgkin’s 
lymphoma cell line that constitutively expresses CD30 (22) was also used as a positive 
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control. All EC cell lines expressed CD30 but also contained a fraction of CD30–/dim cells, 
which were more prominent in the Tera-1 cell line (Fig. 1A). We next examined CD30 
expression by immunohistochemistry (IHC) in human tissue microarrays (TMA) that 
include normal testes, seminomas, and NS-TGCTs. Normal testes and seminomas did not 
display CD30 staining (Fig. 1B). In contrast, up to 70% of EC specimens exhibited a 
moderate to strong, granular, membranous and Golgi CD30 staining pattern (Fig. 1B). When 
the pattern of CD30 expression was scored using computational analysis and analyzed as H 
score (Fig. 1C) or as frequency of positive cells (Fig. 1D), CD30 was routinely expressed 
only by primary ECs (p<0.001, one-way ANOVA), although with some heterogeneity.
CD30.CAR T cells target CD30+ EC cell lines and their side population (SP) cells.
We engineered T cells to express either CD30.28 or CD30.BB CARs (Supplementary Fig. 
S1A). Transduction efficiency was consistently >90% for both constructs (Supplementary 
Fig. S1B), and CD30.CAR T cells expanded in vitro in the presence of cytokines 
(Supplementary Fig. S1C). CD30.CAR T cells showed phenotypic characteristics of stem 
cell-like, effector-memory and central-memory T cells (Supplementary Fig. S1D).
CD30.CAR T cells lysed CD30+ HDLM-2 and Tera-2 tumor cells at higher frequencies 
compared to control T cells (Ctr.Ts), whereas CD30– Raji tumor cells were spared in short-
term 51Cr release assays (Fig. 2A). CD30.CAR T cells also eliminated CD30+ tumor cells in 
long-term coculture experiments. CD30.CAR T cells targeted Lan-1/CD30 cells whereas 
neither control T cells nor CD30.CAR T cells eliminated Lan-1/WT cells (Supplementary 
Fig. S2A). Using effector:target (E:T) ratios ranging from 1:5 to 5:1, both CD30.28 T cells 
and CD30.BB T cells exhibited antitumor activity against all three EC cell lines tested (Fig. 
2B–D and Supplementary Fig. S2B–D). Although CD30.CAR T cells eliminated Tera-1 
(Fig. 2B and Supplementary Fig. S2B) and Tera-2 (Fig. 2C and Supplementary Fig. S2C) 
cells at low E:T ratios (1:1, 1:2 and 1:5), they could only control NCCIT-cell growth at the 
highest 5:1 E:T ratio (Fig. 2D). EC tumor cells do not express the co-stimulatory molecules 
CD80 and CD86, and thus do not provide costimulation to T cells (Supplementary Fig. 
S2E–F). Both CD30.28 T cells and CD30.BB T cells showed proliferation in response to EC 
cells, as assessed by CFSE dilution assays (Supplementary Fig. S3A), confirming both 
endodomains provided co-stimulation. Additionally, CD30.CAR T cells secreted IFNγ and 
IL-2 upon stimulation with EC cells (Supplementary Fig. S3B,C). In summary, CD30.CAR 
T cells showed selective activation by CD30+ EC cells and antitumor activity in vitro.
Cancer stem cells are a subpopulation of tumor cells with stem cell characteristics that can 
contribute to tumor relapse (23). Taking in consideration the germinal origin of ECs, we 
asked whether EC cell lines contain putative cancer stem cells using the Hoechst 33342 
staining for detection of SP cells (24). Although all EC lines had some SP cells, Tera-1 cells 
showed the highest frequency of SP cells (15–30%) (Fig. 3A). SP cells retained expression 
of CD30 (Fig. 3A) and exhibited cancer stem cell characteristics based on the expression of 
the stem cell-associated markers ABCG2 (25) and SOX2 (26) (Fig. 3B), and their capacity 
to differentiate to non-SP cells (24) (Fig. 3C). CD30.CAR T cells targeted sorted SP cells in 
coculture assays (Fig. 3D). Therefore, CD30.CAR T cells can target both differentiated and 
stem cell-like CD30+ EC cells.
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CD30.CAR T cells localize to EC tumors and exhibit antitumor activity in vivo.
To model EC in vivo, we inoculated NSG mice with luciferase-labeled Tera-2 tumor cells 
directly into the testes (20). Tera-2 cells engrafted, as detected by bioluminescence (BLI) 
(Fig. 4A) and retained expression of CD30 in situ as assessed by IHC (Fig. 4B). However, 
tumors engrafted in mouse testes rarely metastasized to extragonadal sites. As 
intraperitoneal or intravenous administration of EC cells in NSG mice resulted in poor tumor 
engraftment and because metastatic TGCTs typically arise in midline locations and 
retroperitoneum (27), we engrafted Tera-2 cells orthotopically under the kidney capsule as a 
clinically relevant model of metastatic EC. In this tumor model, luciferase-labeled 
CD30.CAR T cells injected intravenously via tail vein (i.v.) localized and accumulated at the 
tumor site. Although CD30.BB T cells showed increased accumulation early after injection, 
CD30.28 T cells showed better long-term persistence compared to that of controls (control T 
cells) or CD30.BB T cells (Fig. 4C and Supplementary Fig. S4A). T cells were detectable in 
the blood (Supplementary Fig. S4B) and spleen (Supplementary Fig. S4C) in all treatment 
groups between day 30–45 post T-cell infusion. When analyzed by IHC, tumors were 
located under the renal capsule, sometimes infiltrating into the subjacent cortex or deeper 
into the medulla (Supplementary Fig. S4D). In tumor specimens collected between day 30–
45 post T-cell infusion, we observed infiltrating CD3+ T cells that occasionally formed small 
clusters (Supplementary Fig. S4D). No significant differences in CD3+ T-cell infiltration 
between control T cells and CD30.CAR T-cell treated groups were observed (Fig. 4D), 
likely because the analysis was performed between day 49–56 post tumor inoculation when 
tumor burden is significantly different between groups.
To test CD30.CAR T-cell activity, luciferase-labeled EC cells were engrafted in the kidney 
and tumor growth measured by BLI. When tumors in the kidney showed consistent increase 
in BLI, mice received i.v. unlabeled control T cells or CD30.CAR T cells. Both CD30.28 T 
cells and CD30.BB T cells reduced the tumor growth compared to control T cells (Fig. 4E 
and Supplementary Fig. S4E), but CD30.28 T cells supported better survival when using 
tumor BLI of 5 × 107 p/s as a survival cutoff (Fig. 4F).
CD30– EC cells eliminated by CD30.CAR T cells through cell-cell contact process.
Although not displaying lytic activity against CD30– tumor cells alone in short-term (Fig. 
2A) or long-term (Supplementary Fig. S2A) assays, CD30.CAR T cells eliminated Tera-1 
cells, which contain a mixture of CD30+ and CD30– cells (Fig. 1A), in 5-day coculture 
assays (Fig. 2B). To dissect this phenomenon, we cocultured CD30.CAR T cells with CD30– 
flow-sorted Tera-1 cells (Fig. 5A) and found that they were no longer eliminated (Fig. 5B 
and Supplementary Fig. S5A), with no detectable IFNγ or IL-2 released in culture 
supernatants (Supplementary Fig. S5B). In addition, when unselected Tera-1 cells were 
cocultured with CD30.CAR T cells at low E:T ratios, CD30+ Tera-1 cells were preferentially 
eliminated over the CD30– fraction (Fig. 5C). Similar results were observed with CD30.BB 
T cells (Supplementary Fig. S5C). We found no evidence of CD30 upregulation in CD30– 
Tera-1 cells when these cells were exposed to soluble factors released by CD30.CAR T cells 
such as IFNγ and TNFα, or when exposed to coculture supernatants (Supplementary Fig. 
S5D). By contrast, we observed that Tera-1 cells were eliminated in a CD30 antigen-
independent manner by activated CAR T cells. To conclusively support this observation, we 
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cocultured Tera-1 cells with CD19.CAR T cells, which target the CD19 antigen that is not 
expressed by EC cells, in the presence of CD19– (K562/WT) or CD19+ (K562/CD19+) 
target cells to induce CAR T-cell activation. As shown in Fig. 5D, CD19.CAR T cells 
eliminated Tera-1 cells only in the presence of K562/CD19+ cells. Furthermore, the 
elimination of Tera-1 cells was T cell-tumor cell contact-dependent since the antitumor 
effects were abolished when CD19.CAR T cells and K562/CD19+ cells were separated from 
Tera-1 cells using a transwell (Fig. 5E). These data suggest that CD30.CAR T cells, upon 
activation through the CAR, can eliminate the fraction of Tera-1 cells that is CD30– in a cell-
cell contact dependent, but antigen-independent mechanism.
Fas/FasL pathway mediates elimination of CD30– EC cells by CD30.CAR T cells.
Fas-FasL (CD95/CD95L) interactions between tumor cells and cytotoxic T lymphocytes 
contribute to tumor cell death (28). CAR T cells also upregulate FasL upon receptor 
engagement (29;30), and Tera-1 cells express Fas (Fig. 6A). Since the CD30– fraction of 
Tera-1 cells also retains Fas expression (Fig. 6B), we investigated whether CD30.CAR T 
cells utilize the Fas/FasL pathway to eliminate the CD30– fraction of Tera-1 cells. CD30.28 
T cells upregulated FasL upon CAR engagement with EC cells after 4 hours in vitro (Fig. 
6C). In contrast, EC cell lines did not express FasL mRNA (Supplementary Fig. S6A). 
When cocultured with CD30.28 T cells, the CD30– fraction of Tera-1 cells showed caspase 3 
activity (Fig. 6D), which is triggered by the Fas/FasL pathway (28). By contrast, cell death 
of the CD30+ fraction was caused by granzyme B/perforin-mediated membrane damage as 
detected by cleaved caspase 7 (31;32) (Fig. 6E). When CD95 was knocked down in Tera-1 
cells via specific siRNA (14) (Tera-1/CD95 KD, Fig. 6F), we found reduced caspase 3 
activity among CD30– Tera-1 cells compared to wildtype Tera-1 cells when cocultured with 
CD30.28 T cells (Fig. 6G). No difference in activation-induced cell death as measured by 
Annexin V/7AAD staining was observed in CD30.CAR T cells when cocultured with Fas-
sufficient Tera-1 (Tera-1/WT) or Fas-knockdown Tera-1 (Tera-1/CD95 KD) cells 
(Supplementary Fig. S6B). Similar Fas/FasL-mediated effects were observed when the 
experiments were repeated using CD30.BB T cells (Supplementary Fig. S6C–F).
Ectopic Fas expression on tumor cells improves CAR T-cell activity.
To assess if the pattern of antigen-independent Fas/FasL mediated elimination of tumor cells 
was broadly applicable, we evaluated CD95 on the two other EC tumor cell lines Tera-2 and 
NCCIT. Tera-2 cells that express CD95 (Fig. 6A) were similarly targeted via antigen-
independent Fas/FasL killing by CD19.CAR T cells (Supplementary Fig. S7A), but not 
NCCIT cells (Supplementary Fig. S7B) that lack CD95 expression (Fig. 6A). NCCIT cells 
appeared constitutively more resistant to CD30.CAR T cell–mediated killing (Fig. 2D and 
Supplementary Fig. S7C) and showed significantly decreased expression of apoptosis-
related genes by RNA-Seq (including p53, Fas, and TRAIL receptor) compared to either 
Tera-1 or Tera-2, which showed greater coclustering of apoptosis-related gene expression 
patterns (Supplementary Fig. S7D and Supplementary Table S1). However, when engineered 
to express CD95 (NCCIT/CD95+, Fig. 7A), NCCIT cells were more efficiently eliminated 
by CD30.28 T cells (Fig. 7B).
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We further assessed whether Fas/FasL interactions are relevant for other tumor models by 
utilizing the neuroblastoma cell line SH-SY5Y, which contains a fraction of both GD2bright 
and GD2dim cells (Fig. 7C) and also lacks CD95 expression (Fig. 7D). When cocultured 
with GD2-redirected CAR T cells with the CD28 endodomain (GD2.28 T cells), GD2bright 
cells were eliminated, but not GD2dim cells (Fig. 7E). Similar to NCCIT cells, when SH-
SY5Y cells were engineered to express CD95 (SH-SY5Y/CD95+; Fig. 7F), these tumor cells 
were eliminated more readily by GD2.28 T cells (Fig. 7G). These data suggest that 
introducing functional Fas/FasL interactions via ectopic CD95 expression on resistant tumor 
cells is sufficient to improve CAR T-cell activity.
Discussion
Although CAR T-cell therapies have shown promise for treatment of hematological 
malignancies, barriers remain to successful use of these immunotherapies for solid tumors. 
Among these barriers is the diversity of expression of most targetable molecules among 
tumor cells, which invariably leads to tumor escape (33;34). Here, we demonstrated first the 
antitumor activity of CD30.CAR T cells against CD30+ ECs Tera-1 and NCCIT, in support 
of the use of CD30.CAR T cells as a form of immunotherapy for CD30+ TGCTs. Second, 
we discovered a mechanistic link between the lytic activity of CD30.CAR T cells (or 
antigen-specific CAR T cells in general) against bystander antigenneg/dim tumor cells and the 
Fas/FasL pathway. Furthermore, we showed that ectopic Fas expression in otherwise Fas– 
tumor cells enhanced CAR T-cell mediated tumor elimination. Our data suggests that tumor 
evasion resulting from antigen loss may be compensated by the activation of the Fas/FasL 
pathway in CAR T cells. Our results pave the way to leverage Fas expression in ostensibly 
Fas– tumor cells as a means to enhance CAR T-cell mediated tumor elimination.
Few new drugs for the treatment of ECs and TGCTs have been developed in the past few 
decades. Although orchiectomy is curative in patients with localized (i.e. stage 1) NS-
TGCTs (35), patients with metastatic disease and those presenting with primary mediastinal 
tumors, even when cured, often develop long-term chemotherapy-related side effects that 
reduce their life expectancy (36). In addition, the outcome for patients who relapse after 
chemotherapy remains poor with an overall survival rate of only 30–40% (37). CD30 
expression by ECs can be exploited to develop targeted therapies in these malignancies. 
Targeting CD30 by brentuximab vedotin, toxin-conjugated anti-CD30, has shown promising 
results in relapsed TGCT patients (38;39). Here we propose CD30.CAR T cells as an 
alternative to enhance the therapeutic index of CD30-targeted therapies in ECs, extending 
our previous observation in CD30+ lymphomas (13). In our preclinical study using CD30+ 
ECs, we show that CD30.CAR T cells can target human EC cell lines, localize to the tumor 
site in vivo and control tumor growth.
The presence of the EC subtype among NS-TGCTs correlates with higher rates of relapse 
after chemotherapy (3), which may be driven, at least in part, by the intrinsic stem cell 
properties of ECs (26). Cancer stem cells, which differentiate into multiple tumor cell types, 
are often resistant to chemotherapy and act as a reservoir of tumor cells that leads to 
recurrence (40). Herszfeld et al. linked CD30 expression to enhanced tumorigenic features 
among transformed hematopoietic stem cells (10). Because CD30 expression is retained by 
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putative EC stem cells identified as SP cells (24), targeting this molecule with CAR T cells 
may prove advantageous for overcoming the drug resistance of these tumor cells.
The observed Fas-FasL interaction between ECs and CD30.CAR T cells may represent a 
way to overcome tumor escape associated with antigen heterogeneity. We observed that 
CD30.CAR T cells can target CD30– EC cells in a contact-dependent manner via Fas/FasL 
interaction. While eradicating CD30+ EC cells via perforin/granzyme B-mediated 
mechanisms, CD30.CAR T cells also upregulate FasL and eliminate surrounding CD30– 
tumor cells, if they express the CD95 molecule, via caspase 3 activation. The Fas/FasL 
pathway is relevant in tumor immunology (41), and Fas agonist mAbs have been developed 
to activate the apoptotic cascade in tumor cells (42). However, this strategy was not 
clinically developed due to the systemic toxicities caused by the nonselective targeting of 
CD95-expressing cells in normal tissues, such as hepatocytes (43). In this regard, the FasL 
mechanism exploited by CAR T cells, which is cell-cell contact dependent, is more 
regulated than systemic Fas targeting by mAbs, since upregulation of FasL by CAR T cells 
only occurs at the tumor site after antigen-specific engagement.
Although our data indicate that the Fas/FasL pathway is critical for CD30.CAR T cells to 
eliminate surrounding antigenneg tumor cells, tumor cells can still escape immune cell 
targeting due to tumor-associated dysfunctions of the Fas/Fas-L pathway. For example, 
tumor cells can downregulate Fas by competition of Fas isoforms or impairment of surface 
Fas expression (41) or, in the case of EC, develop non-functional Fas mutations (44). In the 
examples of tumor escape due to alternatively spliced isoforms (5) or antigen loss (6) after 
CAR T-cell therapy, it is also plausible that endogenous Fas is dysfunctional in these tumors 
and thus CAR T cells are unable to eliminate antigenneg tumor cells using the Fas/Fa-L 
mechanism. The EC cell line NCCIT and the neuroblastoma cell line SH-SY5Y are 
examples of Fas– tumor cell lines. We observed that these cell lines are indeed more resistant 
to the cytolytic activity of CD30.CAR T cells. This effect can be reversed, however, by 
promoting the expression of functional Fas in tumor cells. These data thus highlight a 
strategy to exploit the Fas/FasL pathway in adoptive T-cell immunotherapy and specifically 
in CAR T-cell therapies. For example, a clinical translation of the effect we have described 
may be achieved by the use of oncolytic viruses engineered to promote the expression of 
functional CD95 in tumor cells in vivo, which would further extend our previous observation 
that armed oncolytic viruses and CAR T cells can cooperate in attacking the tumor (45).
Although effective in targeting CD30+, CD30– EC cells, and EC stem-like EC cells in vitro, 
CD30.CAR T cells did not completely eradicate EC tumors in vivo in our aggressive EC 
model in which the tumor is engrafted within the kidney. CD30.CAR T cells upon i.v. 
inoculation localized at the tumor and showed some expansion within the tumor. However, 
the observed localization, expansion and persistence of CD30.CAR T cells in our model was 
unable to fully eradicate the tumor. Several strategies have been proposed to further enhance 
CAR T-cell migration, infiltration and persistence within the tumor, such as engineering 
CAR T cells to express heparanase to degrade tumor extracellular matrix (21) or constitutive 
expression of cytokines (46). In addition, combination with other agents may also improve 
the antitumor activity of CAR T cells. For instance, PD-L1 is expressed in some EC tumors 
(47). Although PD1/PD-L1 blockades may not be effective as single agents in TGCTs due to 
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its low mutation rates (48), these inhibitors may prevent the exhaustion of CD30.CAR T 
cells that express PD1 upon activation (49).
In summary, our data suggest that CD30.CAR T cells represent a clinically applicable 
immunotherapy strategy for patients with ECs. We demonstrated that CD30.CAR T cells are 
effective against ECs targeting both differentiated and stem cell-like EC cells. We also 
highlighted the relevance of the Fas/FasL pathway in CAR T-cell function and how this 
pathway can be exploited to counter tumor escape due to the downregulation of the targeted 
antigen by tumor cells, as well as to enhance cytolytic activity of CAR T cells. Finally, 
because CD30 is expressed in other solid tumors such as neoplasms with chondroid 
differentiation, which have dismal outcomes (50), CD30.CAR T cells represent a promising 
treatment avenue for other CD30+ non-lymphomatous malignancies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CD30 is expressed by EC cell lines and primary ECs.
(A) CD30 expression was detected on EC tumor cell lines Tera-1, Tera-2 and NCCIT by 
flow cytometry using anti-human CD30 (Clone Ber-H3). The neuroblastoma cell lines 
Lan-1/WT and Lan-1/CD30 were used as CD30 negative and positive control, respectively. 
The Hodgkin’s lymphoma cell line HDLM-2 was used as a naturally-expressing CD30 
control tumor cell line. Frequency of positive cells and mean fluorescent intensity (MFI) are 
indicated. (B) Representative IHC for CD30 expression with nuclear counterstain in human 
tissue microarray (TMA) including normal testes, seminoma (stage I T1N0M0), and ECs 
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(stage I T2N0M0) at 10X magnification, scale bar=100μm. IHC was performed using anti-
human CD30 (Clone Ber-H2). (C,D) Cumulative analysis of CD30 expression for the TMA 
shown as H score (C), an algorithm calculated based on membrane staining frequency and 
intensity, or as frequency of positive cells (D). For both panels, each data point represents 
one tissue sample with mean ± SEM for each group of tissues/tumors. ***=p<0.001, one-
way ANOVA.
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Figure 2. CD30.CAR T cells exhibit cytotoxic activity against EC cell lines in vitro.
(A) 51Cr release assay of control T cells (Ctr.T), CD30.28 T cells and CD30.BB T cells 
against tumor cell lines indicated (mean ± SEM, n = 4 independent experiments). ns=not 
significant, *=p<0.05, **=p<0.01, ***=p<0.001, repeated measures one-way ANOVA 
comparing individual effector:target (E:T) ratios. (B-D) Control T cells or CD30.CAR T 
cells were cocultured with the EC cell line Tera-1 (B), Tera-2 (C) or NCCIT (D). By day 5, 
remaining EC cells (CD30+) and T cells (CD3+) were collected and analyzed by flow 
cytometry. Representative flow plots at 1:1 (B,C) or 5:1 (D) E:T ratios (left panels) and 
Hong et al. Page 18













cumulative data for remaining frequency of CD30+ cells for all E:T ratios tested (right 
panels) are shown (mean ± SEM, n = 4–5 independent experiments). *=p<0.05, **=p<0.01, 
***=p<0.001, two-sided, paired Student’s T test.
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Figure 3. EC-derived SP cells are targeted by CD30.CAR T cells.
(A) Flow cytometry plots of Hoechst 33342-stained tumor cell lines in which percentages of 
SP and non-SP cells are shown for each tumor cell line (upper panels). Histograms of CD30 
expression and MFI on pre-gated SP and non-SP cells are shown (lower panels). Raji cells 
were used as CD30– control cells. (B) Tera-1 SP and non-SP cells were identified by dye 
cycle violet staining and FACS-sorted. RNA was extracted, retro-transcribed and amplified 
by RT-qPCR to measure the expression of the stem cell markers ABCG2 and SOX2. Each 
bar represents the mean ± SEM of three biological replicates. (C) SP cells were sorted from 
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the Tera-1 cell line and cultured in vitro for 6 weeks. SP-sorted cells regenerated both SP 
and non-SP cells. (D) Control T cells or CD30.CAR T cells were cocultured with SP-sorted 
Tera-1 cells at a 1:1 E:T ratio for 5 days, followed by flow cytometry analysis to detect 
remaining CD3+ T cells and CD30+ tumor cells. Flow cytometry plots of one representative 
independent experiment are shown (n = 2).
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Figure 4. CD30.CAR T cells localize to EC tumors and exhibit antitumor activity in vivo.
(A) Representative in vivo IVIS imaging of NSG mice inoculated with 2 × 106 Tera-2 cells 
labeled with eGFP-FFLuc into the left testis. (B) Representative hematoxylin/eosin (H&E) 
and human CD30 IHC staining of EC tumors growing in the testis are shown at 4X 
magnification, scale bar=250 μm. (C) NSG mice were inoculated with Tera-2 cells under the 
left kidney capsule and, 21 days later, infused i.v. with 1 × 107 eGFP-FFLuc-labeled 
CD30.CAR T cells or CD19.CAR T cells (irrelevant T cells). Representative IVIS images 
indicating CAR T-cell localization and expansion (left panel) and cumulative BLI (right 
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panel) are shown (mean ± SEM, n=3–4 per group, 2 independent experiments). **=p<0.001, 
one-way ANOVA at day 12. (D) T-cell treated mice were sacrificed at day 30–45 post tumor 
inoculation and tumors were stained with anti-human CD3 to detect tumor-infiltrating T 
lymphocytes. CD3+ T cells were counted at 400x magnification with the tumor covering at 
least 80% of the field of view in a blinded fashion. Cumulative quantification of CD3+ T-cell 
counts are shown (mean ± SEM, n=1–3 per group, 4 independent experiments). ns=not 
significant, one-way ANOVA. (E) NSG mice were inoculated with Tera-2 cells labeled with 
eGFP-FFLuc under the left kidney capsule and received 1 × 107 CD30.CAR T cells or 
CD19.CAR T cells (Ctr.T) i.v. by day 15. Representative IVIS images indicating tumor 
growth (left panel) and cumulative BLI (right panel) are illustrated (mean ± SEM, n = 4–5 
per group, 2 independent experiments). **=p<0.001, one-way ANOVA at day 42. (F) 
Cumulative Kaplan-Meier survival curve of BLI <5 × 107 p/s for 2 independent experiments. 
*=p<0.05 by log-rank (Mantel-Cox) test.
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Figure 5. CD30.CAR T cells eliminate Tera-1 CD30– cells in a cell contact-dependent but 
antigen-independent manner.
(A) Tera-1 cells were FACS-sorted to obtain CD30+ and CD30– cells. Histogram shows 
CD30 expression on sorted cells. (B) Sorted Tera-1 CD30+ and CD30– cells were labeled 
with CFSE and cocultured with either control T cells or CD30.28 T cells for 5 days. Cells 
were then collected and evaluated by flow cytometry to quantify T cells (CD3+) and tumor 
cells (CFSE+). Representative flow plots (top panels) and cumulative data (bottom panels) 
summarizing CFSE+ tumor cell frequency (mean ± SEM, n = 4 independent experiments) 
are shown. ns = not significant, **=p<0.01, two-sided, paired Student’s T test. (C) Tera-1 
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cells were labeled with CFSE and cocultured for 5 days with CD30.28 T cells at decreasing 
E:T ratios ranging from 1:1 to 1:15. Representative plots (left columns) and CD30 
histograms (right columns) of CFSE+ Tera-1 cells with cumulative data (right graph) for 
remaining tumor cells calculated with flow cytometry-based counting beads are shown 
(mean ± SEM, n = 5 independent experiments). *=p<0.05, **=p<0.01, two-sided, paired 
Student’s T test. (D) Tera-1 cells were cocultured with CD19.CAR T cells in the presence of 
either K562/WT or K562/CD19+ cells at 1:1:1 ratio for 5 days. Cells were then collected 
and evaluated by flow cytometry to quantify T cells (CD3+) and tumor cells (CD30+). 
Shown are representative flow cytometry plots of CD3+ T cells and CD30+ EC cells pre-
gated to exclude CD33+ K562 cells (left panels) and cumulative data summarizing tumor 
cell numbers (right panels). Dashed line represents the initial Tera-1 cell number (mean ± 
SEM, n=5 independent experiments). *=p<0.05, two-sided, paired Student’s T test. (E) 
Tera-1 cells were plated in the lower chamber of a 0.4μm transwell-plate 24 hours prior to 
plating CD19.CAR T cells and either K562/WT or K562/CD19+ cells in the upper chamber 
at 1:1:1 ratio for 5 days. Tera-1 cells in the lower chamber were then collected and counted 
by flow cytometry. Cumulative data are shown, dashed line represents the initial cell number 
(mean ± SEM, n = 7 independent experiments). ns = not significant, *=p<0.05, two-sided, 
paired Student t test.
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Figure 6. Functional Fas-FasL interaction is critical for the elimination of CD30– EC cells.
(A) Flow cytometry histograms showing CD95 expression and MFI in EC cell lines. T cells 
stimulated with anti-CD3/CD28 mAbs were used as positive control for CD95 expression. 
(B) CD95 expression on pre-gated CD30+ or CD30– Tera-1 cells. (C) RT-qPCR cumulative 
data for FasL mRNA expression among control T cells or CD30.28 T cells cultured alone or 
with EC cells at a 5:1 E:T ratio for 4 hours at 37°C (mean ± SEM, n = 6 independent 
experiments). FasL mRNA expression was normalized to β-actin mRNA. ns = not 
significant, ***=p<0.0001, two-sided paired Student’s T test. (D-E) Active caspase 3 and 
cleaved caspase 7 were assessed by flow cytometry in Tera-1 cells cocultured with control T 
cells or CD30.28 T cells at 1:2 or 1:5 E:T ratio for 18 hours, respectively. Representative 
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flow plots (left panels) and cumulative data (right panels) of active caspase 3 frequency (D) 
or cleaved caspase 7 MFI (E) among Tera-1 CD30– and CD30+ cells, respectively are shown 
(mean ± SEM, n = 5 independent experiments). *=p<0.05, **=p<0.01, two-sided, paired 
Student’s T test. (F) CD95 expression on pre-gated CD30– cells for Tera-1/WT or Tera-1 
cells transduced with CD95 shRNA and FACS-sorted based on CD95– expression (Tera-1/
CD95 KD) is shown. CD95 frequency and MFI for Tera-1/CD95 KD cells are indicated. (G) 
Tera-1/WT or Tera-1/CD95 KD cells were cocultured with control T cells or CD30.28 T 
cells at 1:5 E:T ratio for 18 hours. Representative flow plots (left panels) and cumulative 
data (right panels) for active caspase 3 among Tera-1 CD30– cells are shown (mean ± SEM, 
n = 4 independent experiments). ns = not significant, ***=p<0.001, two-sided, paired 
Student t test.
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Figure 7. Functional Fas expression is sufficient to improve CAR T-cell activity.
(A) CD95 expression on NCCIT/WT cells and NCCIT cells transduced to express CD95 
(NCCIT/CD95+). CD95 frequency and MFI for NCCIT/CD95+cells are indicated. (B) 
NCCIT/WT or NCCIT/CD95+ cells were cocultured with control T cells or CD30.28 T cells 
at 1:2 E:T ratio for 5 days. Representative flow plots (left panels) and cumulative data (right 
panels) showing remaining tumor cells are illustrated (mean ± SEM, n = 4 independent 
experiments). ns = not significant, *=p<0.05, two-sided, paired Student’s T test. (C-D) Flow 
cytometry histograms showing GD2 (C) or CD95 (D) expression and/or MFI in SH-SY5Y 
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cells. (E) Control T cells or GD2.CAR T cells were cocultured with SH-SY5Y cells at a 1:5 
E:T ratio for 5 days. Remaining tumor cells were collected and absolute numbers of 
GD2bright and GD2dim cells were calculated by flow cytometry-based counting beads (mean 
± SEM, n = 7 independent experiments). (F) CD95 expression pre-gated on GD2dim SH-
SY5Y/WT cells and SH-SY5Y cells transduced to express CD95 (SH-SY5Y/CD95+). CD95 
frequency and MFI for SH-SY5Y/CD95+ cells are indicated. (G) SH-SY5Y/WT or SH-
SY5Y/CD95+ cells were cocultured with control T cells or GD2.28 T cells at 1:5 E:T ratio 
for 5 days. Representative flow plots (left panels) and cumulative data (right panels) showing 
remaining tumor cells using B7H3 as a tumor cell marker are illustrated (mean ± SEM, n = 5 
independent experiments). ns = not significant, **=p<0.01, two-sided, paired Student t test.
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